Loading
Every dated change on the records linked to Squamous cell carcinoma of the lung, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Median overall survival not reached vs 14.
Nivolumab plus ipilimumab did not improve survival over nivolumab alone; the trial closed for futility.